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and public oncology centers in Brazil. RESULTS: Treatment was received by 161
eligible patients. The majority of patients were men (54.5%), and 30.3% were first
diagnosed at stage IV. Across up to three lines of treatment, 76.4% received sys-
temic therapy, 57.8% had surgery, 37.9% received radiotherapy and 9.3% received
supportive care. Among first line treatment, 30.4% received systemic treatment
only and 42.2% systemic in combination with surgery and/or radiotherapy. Second
line treatment was administered to 67 patients; of those, 88.1% had systemic treat-
ment, 9.0% received surgery, and 10.4% received radiotherapy. Only 26 patients
received third line treatment. Outside clinical trial, the most commonly-used drug
alone or in combination on first-line was Dacarbazine in both public (82.3%) and
private (68.0%) systems, followed by Interferon in the public system (25.8%) and
Interleukin in the private system (40.0%). The mean duration of systemic treatment
was 17.6 (95% confidence interval (CI) 14.1-21.2) weeks. For second line, the most
commonly-used drug was Paclitaxel (31.2%) for private system and Interferon and
Paclitaxel (both 24.0%) for public system. Mean systemic treatment duration was
11.8 (95% CI 7.2-16.4) weeks. In third line, Fotemustine and Dacarbazine were the
most commonly-used drugs. CONCLUSIONS: In Brazil the most common treat-
ment for unresectable stage III and IV melanoma is systemic treatment combined
with surgery and/or radiotherapy. The most comonly used agent in first line is
Dacarbazine; most common second line treatments are Paclitaxel and Interferon.
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RESULTS FROM THE TURKISH LEAGUE AGAINST RHEUMATISM RA REGISTRY
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OBJECTIVES: This study investigates the demographic and clinical characteristics
of patients with rheumatoid arthritis (RA) in Turkey and attempts to inform strat-
egies for the prevention, treatment, and support of RA. METHODS: In the present
study, 2359 patients with RA from 43 centers across Turkey and who were listed in
the Turkish League Against Rheumatism (TLAR) RA Registry were evaluated. Their
demographic and clinical data were recorded. Disease activity, functional status,
and radiographic damage were measured using the Disease Activity Score-28 (DAS-
28), the Health Assessment Questionnaire (HAQ), and van der Heijde modified
Sharp scoring method. Disease activity status was defined according to EULAR
criteria. RESULTS: The mean age of the sample was 51.6  12.5 years; 83.3% (1966)
were women and 16.7% (393) were men. The mean duration of education was
5.22  3.84 years, and 74.6% were homemakers. The mean disease duration was
11.9  8.7 years. Exercise habits, smoking habits, and alcohol consumption were
present in 7.1%, 16.2%, and 2.0%, respectively. The most common extra-articular
signs were those involving the eye (4.8%). Co-morbid diseases were observed in
57.1% of the patients. Nonbiological disease-modifying anti-rheumatic drugs
(DMARDs) were used by 91.0% of the patients, while 10.2% used biological DMARDs.
The mean DAS-28, HAQ, and Sharp scores were 4.04 1.46, 0.38 0.37, and 31.25
57.18, respectively. Patients who were in remission and had low disease activity
rates comprised 17.8% and 14.1% of the sample respectively, while 42.7% and 25.5%
had moderate and high disease activity rates, respectively. CONCLUSIONS: The
majority of patients with RA in Turkey are middle-aged and homemakers. The
level of education that important for compliance and success of treatment was
low. Despite the high use of DMARDs, the majority of patients have moderate
and high disease activities. This finding may suggest that the current treatment
is insufficient.
PMS2
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OBJECTIVES: To investigate the clinical efficacy of NNC0109-0012 (anti-IL-20 mAb)
on physical function and disability in Rheumatoid Arthritis (RA) patients with ac-
tive disease on stable MTX but inadequate response (MTX-IR) in a phase 2a multi-
centre, randomised, double-blind, placebo-controlled, parallel group trial.
METHODS: Sixty-seven patients were randomised to once-weekly dosing of
NNC0109-0012 (n45) or placebo (n22) for 12 weeks and followed for additional 13
weeks. Of the 67 randomised patients 43 were Rheumatoid Factor (RF)- and anti-
Cyclic Citrullinated Protein (anti-CCP)-positive. Physical function and disability
was assessed by the patient-reported outcome measure Health Assessment Ques-
tionnaire – Disability Index (HAQ-DI). HAQ-DI was assessed weekly from baseline
to week 12 and additionally 3 times in the 13 weeks follow-up period. A mixed-
effects model repeated measures was fitted to change in HAQ-DI score including
treatment, time and interaction between treatment and time as fixed factors; base-
line HAQ-DI score and interaction between time and baseline HAQ-DI score as
continuous covariates and subject as random effect. RESULTS: Physical function
was not significantly improved for NNC0109-0012 compared to placebo after end of
treatment at 12 weeks (-0.26, p0.130) for all randomised patients. In RF- and
anti-CCP-positive patients physical function was significantly improved after both
12 and 25 weeks (p0.047 and p0.022, respectively). The estimated mean change
in HAQ-DI for RF- and anti-CCP-positive patients at 12 and 25 weeks were -0.60 and
-0.63 for NNC0109-0012, and -0.15 and -0.16 for placebo. The percentage of RF- and
anti-CCP-positive patients that achieved the criteria for the minimum clinical im-
portant difference (HAQ-DI0.22 units) at 25 weeks was significantly higher
(p0.046) for the NNC0109-0012 treated patients compared to placebo with 76% (22
of 29 patients) versus 43% (6 of 14 patients). CONCLUSIONS: Treatment with
NNC0109-0012 in MTX-IR RA patients on stable MTX effectively improved physical
function and disability in RF- and anti-CCP-positive patients.
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OBJECTIVES: To investigate the effects of NNC0109-0012 (anti-IL-20 mAb) on pa-
tient-reported pain and global disease activity in Rheumatoid Arthritis (RA) pa-
tients with active disease on stable MTX but inadequate response (MTX-IR) in a
clinical phase 2a trial. METHODS: 67 patients were randomised to once-weekly
dosing of NNC0109-0012 or placebo for 12 weeks and followed for 13 additional
weeks. 43 patients were Rheumatoid Factor (RF)- and anti-CCP-positive. The level
of pain and global disease activity was recorded on a 100 mm Visual Analogue Scale
(VAS) by the patients and assessed weekly from baseline to week 12 and addition-
ally 3 times in the 13 week follow up period. A mixed-effects model repeated
measures was fitted to the change for each of the VAS scales including treatment,
time and interaction between treatment and time as fixed factors; baseline VAS
score and interaction between time and baseline VAS score as continuous covari-
ates and subject as random effect. RESULTS:The average baseline pain and disease
activity were 67 and 68 mm (NNC0109-0012) and 71 and 70 mm (placebo). In all
randomised patients, pain was significantly reduced for NNC0109-0012 compared
to placebo after 12 weeks with a mean difference of -15 mm (p0.034) and was -13
mm (p0.046) at week 25. Global disease activity was significantly lower in all
randomised patients for NNC0109-0012 compared to placebo after 12 weeks with a
mean difference of -17 mm (p0.018) and maintained throughout the trial to week
25 with -14 mm (p0.031). For both pain and global disease activity the effects were
more pronounced in the RF- and anti-CCP-positive patients with a 1.5-2 fold larger
difference in effect size compared to placebo than was observed for all randomised
patients. CONCLUSIONS: Treatment with NNC0109-0012 (anti-IL-20 mAb) in
MTX-IR RA patients on stable MTX improved both pain and global disease activity.
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OBJECTIVES: Biologic therapy constitutes the current mainstay of rheumatoid ar-
thritis (RA) patients treatment who have inadequately responded to methotrexate
(MTX-IR). The objective of this study was to compare the relative efficacy, safety
and tolerability of abatacept subcutaneous (sc) vs. all relevant comparators in
MTX-IR patients with RA.METHODS:A systematic literature review identified clin-
ical trials investigating the efficacy, safety and tolerability of abatacept intravenous
and sc, adalimumab, certolizumab, etanercept, infliximab, golimumab, tocili-
zumab and anakinra in combination with MTX. The efficacy endpoints were:
Health Assessment Questionnaire (HAQ) change from baseline (CFB), American
College of Rheumatology (ACR) 20/50/70 response rates, and Disease activity score
28 joints (DAS28) remission rates defined as DAS282.6, after 24 and 52 weeks of
treatment. Safety and tolerability endpoints were: incidence of serious adverse
events (AE), infections, serious infections, withdrawals for any reason, due to AE or
due to lack of efficacy. Results were analysed using indirect treatment comparison
methods estimating the expected relative effect of treatments, and were expressed
as the difference in HAQ CFB and the Risk Ratio of achieving an outcome and
associated 95% Credible Intervals. RESULTS: The analysis of HAQ CFB showed that
abatacept sc is expected to show a relative efficacy comparable to other biologic.
Furthermore, abatacept sc showed ACR20/50/70 response rates and DAS28 remis-
sion rates comparable to other biologic treatments at both time periods. Abatacept
sc is expected to show a comparable safety and tolerability to other biologic treat-
ments, having a similar incidence of serious AE, infections, serious infections,
withdrawals for any reason, due to AE or due to lack of efficacy. CONCLUSIONS:
Considering the assumptions of a NMA, abatacept sc is expected to produce similar
HAQ CFB, ACR20/50/70 and DAS28 rates and a similar incidence of serious AE,
infections, serious infections and withdrawals compared to other biologics in
MTX-IR RA patients.
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OBJECTIVES: To compare treatment-related risks versus improvements in out-
comes in terms of net health benefit (NHB) for 3 treatments for moderate-to-severe
rheumatoid arthritis: the anti–tumor necrosis factor drugs (anti-TNFs) adali-
mumab (ADA) and infliximab (IFX), both in combination with methotrexate (MTX),
and MTX alone.METHODS:A simulation model was developed in which a cohort of
rheumatoid arthritis patients initiating treatment progressed at 6-month intervals
for 10 years or until withdrawal from therapy. NHB, measured in discounted qual-
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ity-adjusted life-years (QALYs), was calculated for patients receiving ADAMTX,
IFXMTX, and MTX alone. Outcomes were examined separately for MTX-naïve and
disease-modifying antirheumatic drug (DMARD)–failure patients. Treatment ben-
efits were measured by American College of Rheumatology 20, 50, and 70 responses
and translated into improvements in Health Assessment Questionnaire Disability
Index scores. Risks comprised loss of drug efficacy and adverse events; patients
could withdraw from treatment due to either. Benefits and risks were associated
with increments and decrements in QALYs, respectively. Data were derived from
the published literature and drug prescribing information. RESULTS: MTX-naïve
patients on ADAMTX, IFXMTX, and MTX alone withdrew after 3.31, 2.46, and
2.71 years and accrued NHBs of 1.40, 1.05, and 1.08 QALYs, respectively. Thus,
MTX-naïve patients on ADAMTX accrued incremental NHBs of 0.35 (P  .05) ver-
sus IFXMTX and 0.32 (P  .05) versus MTX alone. DMARD-failure patients on
ADAMTX, IFXMTX, and MTX alone withdrew after 3.33, 2.11, and 1.44 years and
accrued NHBs of 1.38, 0.86, and 0.57 QALYs, respectively. Thus, DMARD-failure
patients on ADAMTX incurred incremental NHBs of 0.51 (P .05) versus IFXMTX
and 0.81 (P  .05) versus MTX alone. CONCLUSIONS: Understanding the benefit-
risk tradeoff is important for clinicians when prescribing anti-TNFs. Both MTX-
naïve and DMARD-failure patients may experience greater NHB when treated with
ADAMTX than when treated with IFXMTX or MTX alone.
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The GO-REVEAL clinical trial has shown golimumab to be effective in the treatment
of active and progressive PsA. A recently published article by Yang et al. that cov-
ered the NICE technology appraisal process for psoriatic arthritis (TA220) presented
an indirect comparison that suggested differences in treatment effects between
different anti-Tumor Necrosis Factor-ainhibitors (TNFs). OBJECTIVES: To evaluate
the comparative efficacy of anti-TNF drugs for the treatment of PsA in patients with
an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) us-
ing a a critical appraisal of the Yang et al. manuscript and network meta-analysis.
METHODS: The previous indirect comparison was analysed, identified errors cor-
rected, and assumptions altered where necessary. A network meta-analysis was
then performed based on these updated parameters. Indirect comparisons were
performed for the available anti-TNFs (adalimumab, etanercept, golimumab, and
infliximab) measuring relative risks for the PsA response criteria (PsARC), mean
differences for improvements from baseline for the Health Assessment Question-
naire (HAQ) by PsARC responders and non-responders, and mean difference for the
improvements from baseline for the psoriasis area and severity index (PASI). When
the reporting of data on intervention group response rates and improvements were
incomplete, straightforward conversions were used, based on the available data.
RESULTS: All anti-TNFs were significantly better than control. The indirect com-
parison did not reveal any statistically significant difference between the anti-TNFs
using the updated parameters. CONCLUSIONS: There is insufficient statistical ev-
idence to demonstrate differences in efficacy between available anti-TNFs for PsA.
Estimates of effect appear to be sensitive to the analytic approach, so this uncer-
tainly should be taken into account in future economic evaluations.
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NON-VERTEBRAL OSTEOPOROTIC FRACTURES IN PATIENTS WITH
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OBJECTIVES: Chronic inflammation in rheumatoid arthritis (RA) may interfere
with bone remodelling. Small studies have suggested biologic DMARDs preserve
bone mineral density at 6-12 months. Our objective was to determine the risk of
non-vertebral osteoporotic fractures in RA subjects aged50, comparing outcomes
in patients who were exposed or unexposed to biologic DMARDs. METHODS: A
nested case-control study from January 2002 to December 2008 was conducted
using Quebec physician billing and hospital discharge data. RA subjects were iden-
tified from ICD-9/10 codes in billing and hospitalization data. Subjects were fol-
lowed until the earliest of non-vertebral osteoporotic fracture (index date), death,
or end of study period. A validated algorithm identified non-vertebral osteoporotic
fractures from physician claims. Controls were matched to cases (4:1 ratio) on age,
sex, and date of study entry. Biologic DMARD exposure was defined as being on
treatment for 180 days pre-index. Conditional logistic regression was used, ad-
justing for indicators of RA severity, comorbidity, drugs influencing fracture risk,
and measures of health care utilization. RESULTS: Over the study period, 1,803
cases were identified (7,175 controls). The most frequent fracture site was hip/
femur (43.7%). In total, 190 subjects (53 cases, 137 controls) were exposed to biologic
DMARDs. We were unable to demonstrate an association between biologic
DMARDs and fracture risk (Odds Ratio, OR [95% Confidence Interval, CI]: 1.16 [0.51-
2.62]). RA duration had the strongest impact on fracture risk; for subjects of RA
duration10 years (vs.5), the OR was 6.40 (95% CI 3.57-11.46), while those with RA
duration 5-10 years (vs. 5) had an OR of 3.05 (95%CI 1.90-4.89). The inability to
detect an effect remained in sensitivity analyses. CONCLUSIONS: Despite the pos-
itive impact of biologic DMARDs on bone remodelling observed in small studies, we
were unable to demonstrate a reduction in the risk of non-vertebral osteoporotic
fractures in older adults with RA.
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OBJECTIVES: In Italy the epidemiological data and the Dupuytren disease care
practice description are poor and come mainly from extrapolation of data obtained
in other countries. The objective of this study was to assess the prevalence and the
management of this disease in Italy and in the Italian regions. METHODS: Data
have been obtained from CSD LPD General Practitioner’s (GPs) longitudinal data-
base. Patients with at least one diagnosis of Dupuytren disease between October
2008 and September 2010 were selected. Patients were followed-up for 12 months
since the First Diagnosis date. Study results have been stratified by macro areas.
RESULTS: 1.829 patients (62,55% men, 37,45% women) with at least one diagnosis of
Dupuytren disease have been selected. Disease prevalence was estimated at 0,15%
patients nationwide and at 0.178% , 0.229%, 0.123% ,0.082% patients in the Nord-
West, Nord-East, Center and South-Islands respectively. Prevalence increased with
age: 35% of the patients were aged over 65 y. Only 32 % of the patients benefited
from a specialist visit request for the Dupuytren disease during the follow-up pe-
riod; 70,7% of those requests were for orthopedic visits, 13,5% for hand surgery and
7,5% for physiatry. Macro area analysis showed some differences in the specialists
visits distribution. CONCLUSIONS: The prevalence analysis showed a slight differ-
ence among macro areas underlining a major prevalence of the disease in the
Nord-East compared to the South–Islands area. The prevalence of the disease in the
CSD LPD database in Italy was of 0.15% which is significantly lower than that
reported in the literature. This is probably due to the fact that the majority of
Dupuytren published studies were conducted in Nordic countries where the dis-
ease is mainly diffused. Also, the data collection methods and the age groups could
be different, and, further, many researches were carried out in a specialist setting
only.
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OBJECTIVES: To model the annual impact on hospital costs following the introduc-
tion of sugammadex for routine reversal of neuromuscular blockade. METHODS:
An economic model reflecting resource use and costs associated with neuromus-
cular block and its reversal, and residual blockade, was constructed for a typical
Greek hospital. Clinical trial data were used to estimate time savings relating to
shortened reversal in the operating room (OR) for sugammadex compared to
neostigmine and no reversal. Costs of OR time were derived from labor costs for
different types of OR staff. Resource use associated with residual blockade sequelae
(aspiration, hypoxemia, muscle weakness, upper airway obstruction) was esti-
mated from the literature. Annual procedures, utilization of neuromuscular block-
ing and reversal agents, and uptake of sugammadex within a typical Greek hospital
were estimated. Unit costs were based on public data sources or published
literature. RESULTS: If all OR staff modeled (with average staff attendance across
all procedures of 2.4 anesthetists, 3.5 surgeons and 3.7 nurses) can realize time
savings with shortened reversal, use of sugammadex is estimated to save a typical
Greek hospital, using sugammadex in 7,130 procedures annually, 23,717 € per year.
This corresponds to an increase in drug costs of 358,963 €, which is more than fully
offset by a decrease in costs of OR staff and clinical sequelae of residual blockade
(-382,680 €). In a worst case scenario, if only one second degree anesthetist, one
second degree surgeon and one nurse in attendance realize time savings, annual
costs would be increased (198,404 €). Results were sensitive to OR staff costs and
time savings. CONCLUSIONS: Sugammadex for routine reversal of neuromuscular
blockade can potentially lead to cost savings in the Greek health care setting. The
degree to which costs may be saved depends upon which OR staff can realize time
savings with shortened reversal.
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OBJECTIVES: To assess differences in treatment costs for patients with anti-TNFs
for ankylosing spondylitis (AS) and rheumatoid arthritis (RA), according to their
route of administration. METHODS: A budget impact analysis was designed to
study the costs of each administration route, whether administered subcutane-
ously (SC) in the ambulatory setting or administered intravenously (IV) in an out-
patient hospital setting, from the perspective of the French Statutory Health Insur-
ance. Costs and tariffs are official statutory tariffs. The dosages of each treatment
stem from the Summary of Product Characteristics. Costs were followed-up over 2
years (induction  maintenance). For the weight, a gold standard of 70 kg was
considered. Scenarios were modeled for cohorts of 100 patients. Costs for nurse
have been systematically taken into account for each SC injection associated to a
specialist consultation every 3 months. Initially for IV drugs no ambulatory addi-
tional costs and no transportation costs were considered. RESULTS: For AS, the
average cost for SC drugs over 2 years was 23 471€ while it was 31 086€ for infusion
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